

SEQUENCE LISTING

EPO - DG 1

01. 07. 2004

(76)

5 <110> Santaris Pharma A/S
 Elmén, Joacim
 Wahlestedt, Claes
 Liang, Zicai
 Sørensen, Anders Malling
 Ørum, Henrik
 Koch, Troels
 10 <120> Short interfering RNA (siRNA) analogues
 15 <130> 34638PC01
 <140> PCT/DK204/000192
 <141> 2004-03-22
 20 <150> DKPA200300442
 <151> 2003-03-21
 <150> DKPA200301625
 <151> 2003-10-31
 25 <150> DKPA200400145
 <151> 2004-01-30
 <160> 18
 30 <170> FastSEQ for Windows Version 4.0
 <210> 1
 <211> 21
 <212> RNA
 35 <213> Artificial Sequence
 <220>
 <223> Short interfering (siRNA) analogues comprising LNA
 monomers
 40 <400> 1
 cuuacgcuga guacuucgat t
 45 <210> 2
 <211> 21
 <212> RNA
 <213> Artificial Sequence
 <220>
 50 <223> Short interfering (siRNA) analogues comprising LNA
 monomers
 <400> 2
 ucgaaguacu cagcguaagt t
 55 <210> 3
 <211> 21

21

21

2/4

<212> RNA
 <213> Artificial Sequence

5 <220>
 <223> Short interfering (siRNA) analogues comprising LNA monomers

10 <400> 3
 ugagagaaag cacagaaaat t 21

<210> 4
 <211> 21
 <212> RNA
 <213> Artificial Sequence

15 <220>
 <223> Short interfering (siRNA) analogues comprising LNA monomers

20 <400> 4
 uuuucugugc uuucucucat t 21

<210> 5
 <211> 21
 25 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Short interfering (siRNA) analogues comprising LNA monomers

30 <400> 5
 aucugaagaa ggagaaaaat t 21

35 <210> 6
 <211> 21
 <212> RNA
 <213> Artificial Sequence

40 <220>
 <223> Short interfering (siRNA) analogues comprising LNA monomers

45 <400> 6
 uuuuucuccu ucuucagaut t 21

<210> 7
 <211> 29
 <212> DNA
 50 <213> Artificial Sequence

<220>
 <223> SARS 3 target DNA oligo with Xba I overhang

55 <400> 7
 ctagcaaaact gtcaaaccg gtaattttc 29

<210> 8
 <211> 29

3/4

<212> DNA
<213> Artificial Sequence

<220>
5 <223> SARS 3 target DNA oligo with Xba I overhang

<400> 8
gtttgacagt ttgggccatt aaaaggatc 29

10 <210> 9
<211> 21
<212> RNA
<213> Artificial Sequence

15 <220>
<223> siRNA targeting SARS

<400> 9
ggaugaggaa ggcaauuuat t 21

20 <210> 10
<211> 21
<212> RNA
<213> Artificial Sequence

25 <220>
<223> siRNA targeting SARS

<400> 10
30 ttccuacucc uuccguuaaa u 21

<210> 11
<211> 21
<212> RNA

35 <213> Artificial Sequence

<220>
<223> siRNA targeting SARS

40 <400> 11
cugguacgau uucggugaut t 21

<210> 12
<211> 21

45 <212> RNA
<213> Artificial Sequence

<220>
<223> siRNA targeting SARS

50 <400> 12
ttgaccaugc uaaagccacu a 21

<210> 13

55 <211> 21
<212> RNA
<213> Artificial Sequence

<220>

4/4

<223> siRNA targeting SARS

<400> 13
5 acugucaaac ccgguauut t 21

<210> 14
<211> 21
<212> RNA
10 <213> Artificial Sequence

<220>
<223> siRNA targeting SARS

<400> 14
15 ttugacaguu ugggccauua a 21

<210> 15
<211> 21
<212> RNA
20 <213> Artificial Sequence

<220>
<223> siRNA targeting SARS

<400> 15
25 gacaacuccu auucguagut t 21

<210> 16
<211> 21
30 <212> RNA
<213> Artificial Sequence

<220>
<223> siRNA targeting SARS

35 <400> 16
ttcuguugag gaaagcauc a 21

<210> 17
40 <211> 21
<212> RNA
<213> Artificial Sequence

<220>
45 <223> siRNA targeting SARS

<400> 17
cuuacgcuga guacuucgat t 21

<210> 18
50 <211> 21
<212> RNA
<213> Artificial Sequence

<220>
55 <223> siRNA targeting SARS

<400> 18
ttgaaugcga cucaugaagc u 21